WO2015093484A1 - セサミン類高含有組成物 - Google Patents
セサミン類高含有組成物 Download PDFInfo
- Publication number
- WO2015093484A1 WO2015093484A1 PCT/JP2014/083272 JP2014083272W WO2015093484A1 WO 2015093484 A1 WO2015093484 A1 WO 2015093484A1 JP 2014083272 W JP2014083272 W JP 2014083272W WO 2015093484 A1 WO2015093484 A1 WO 2015093484A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- agent
- sesamin
- oryzanol
- improvement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- the present invention relates to improving the solubility of sesamins in fish oil and / or wheat germ oil. More specifically, the present invention relates to an oil / fat composition containing fish oil and / or wheat germ oil, sesamin and ⁇ -oryzanol.
- Sesamin such as sesamin and episesamin improves in-body absorbability when dissolved in fats and oils (Patent Document 1). Therefore, in designing an oil / fat composition containing sesamins, it is important to dissolve as much sesamins as possible in the oil / fat composition. However, the solubility of sesamin in fats and oils is not always good.
- Patent Document 1 has found that medium chain fatty acid glycerides having 8 to 12 carbon atoms can dissolve a large amount of sesamins.
- the present inventor has confirmed that the solubility of sesamin in fats and oils, in particular, the solubility in fish oil and / or wheat germ oil is low. Therefore, it is difficult to blend sesamin in fish oil and / or wheat germ oil at a high concentration. Furthermore, even when sesamins are blended at a low concentration, crystals of sesamin may precipitate during storage. Since crystal precipitation may cause a decrease in absorbability, sesamin must be added to fish oil and / or wheat germ oil in an amount considerably lower than its dissolvable amount.
- the present inventors have improved the solubility of sesamin compounds by combining ⁇ -oryzanol with an oil and fat composition containing fish oil and / or wheat germ oil and sesamin compounds. Found to get. This effect can be prominent when sesamin and ⁇ -oryzanol are used in a specific ratio.
- An oil and fat composition comprising at least one sesamin, at least one ⁇ -oryzanol, and fish oil and / or wheat germ oil.
- 3. The composition according to 1 or 2, wherein the weight of the fish oil and / or wheat germ oil when the total weight of the sesamin is 1 is 100 or less. 4).
- Prevention of internal oxidation in the subject prevention or improvement of hyperlipidemia, improvement of liver function, prevention or improvement of hypertension, prevention of sickness, prevention of aging, prevention or improvement of fatigue, reduction of blood LDL cholesterol, blood neutrality Reduced lipid, prevention of thrombosis, prevention of arteriosclerosis, improvement of learning ability or memory ability, prevention of senile dementia, protection of gastric mucosa, regulation of endocrine, regulation of autonomic nerve, prevention or improvement of psychosomatic disorders, heart Maintaining function, improving blood flow, inhibiting platelet aggregation, improving vascular endothelial function, maintaining visual function, improving stress symptoms, improving depressive symptoms, improving post-traumatic stress disorder symptoms, improving endurance, energy production, frail
- a method comprising administering to a subject the composition according to
- a method for improving the solubility of sesamins in an oil and fat composition comprising at least one sesamin and fish oil and / or wheat germ oil, comprising blending ⁇ -oryzanol with the composition Method.
- the present invention can improve the solubility of sesamins in fish oil and / or wheat germ oil. Therefore, the volume of the oil and fat composition containing sesamin can be reduced and intake can be facilitated. Moreover, since the crystal precipitation during the preservation
- the “oil composition” means a fat that may contain components other than fat. Therefore, the oil and fat composition of the present invention is an oil and fat, and includes at least one sesamin, at least one ⁇ -oryzanol, and fish oil and / or wheat germ oil as a component of the oil and fat. Means what Components such as sesamin and ⁇ -oryzanol are preferably dissolved in the oil or fat, but may not be partially dissolved.
- sesamins as used in connection with the present invention is a generic term for a series of compounds including sesamin and its analogs.
- sesamin analog include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331.
- Specific examples of the sesamin can include sesamin, episesamin, sesaminol, episesaminol, sesamorin and the like, and these stereoisomers or racemates can be used alone or in combination.
- sesamin and / or episesamin can be preferably used.
- sesamin used in the present invention is not limited at all by its form, production method and the like.
- sesamin extracted from sesame oil by a known method for example, the method described in JP-A-4-9331
- sesamin extract or concentrate is usually used.
- commercially available sesame oil (liquid state) can also be used as it is.
- sesame oil liquid state
- the sesamin content is low (usually less than 1%), so when trying to formulate the sesamin necessary to obtain the physiological effects of sesamin, per unit dosage of the formulated composition The volume can become too large, which can cause inconveniences.
- sesamin extract or sesamin concentrate
- the sesamin extract may be made tasteless and odorless by a known means such as activated clay treatment.
- the amount of sesamin in the oil and fat composition is not particularly limited, but a typical amount is 0.1 to 10.0% by weight, preferably 0.2 to 5.0% by weight.
- the content of sesamin can be measured using any known method such as HPLC.
- HPLC method for example, the method described in JP2009-155531A can be referred to.
- ⁇ -oryzanol An important component for improving the solubility of sesamin is ⁇ -oryzanol.
- ⁇ -Oryzanol has blood neutral lipid lowering action (Geriant.med. 19, 1812-1840, 1981), endocrine / autonomic nerve regulating action (Japanese Pharmacology, 75 (4), 399-403, 1979), Various physiological effects such as gastric mucosal protective action (Nippon Pharmacological Journal, 84 (6), 537-542, 1984) are known, and purified products are used to treat hyperlipidemia and psychosomatic disorders (menopause, It is approved as a medicine for treating irritable bowel syndrome.
- ⁇ -oryzanol used in connection with the present invention is a generic term for an ester-linked ferulic acid with triterpene alcohol or plant sterol.
- triterpene alcohol examples include cycloartol, 24-methylenecycloartanol, cycloartanol, and cycloplanol.
- plant sterols examples include campesterol, stigmasterol, ⁇ -sitosterol, and the like. Can be illustrated. In the present invention, these compounds can be used alone or as a mixture.
- ⁇ -Oryzanol is known to be contained in brown rice, corn, barley and the like. ⁇ -oryzanol is also contained in rice bran oil, which is an oil extracted from brown rice. ⁇ -oryzanol is also contained in rice germ oil. Rice germ oil is an oil extracted from rice germ and is usually said to contain about 1.0 to 1.5 w / w% of ⁇ -oryzanol.
- ⁇ -Oryzanol used in the present invention is not limited at all by its origin, form, production method and the like.
- purified ⁇ -oryzanol may be used, commercially available rice germ oil or the like may be used as it is, a concentrate having a high ⁇ -oryzanol content may be used, or a combination thereof may be used. Also good.
- Concentrates of ⁇ -oryzanol are available as, for example, rice germ oil gamma 30 (Tsukino Food Industry Co., Ltd.), ⁇ -oryzanol, oryzadorim V-50, rice bran oil, brown rice germ oil (Oryza Oil Co., Ltd.) It is.
- the amount of ⁇ -oryzanol in the oil and fat composition is not particularly limited, but a typical amount is 0.05 to 20% by weight.
- a known method such as a UV absorbance method or an HPLC method can be appropriately used.
- the sample is dissolved in heptane and the absorbance is measured at the maximum wavelength of absorption near 315 nm as described in the “Quasi-drug raw material standards” and “Food additives other than chemically synthesized products voluntary standards”. This can be quantified.
- fish oil as used in connection with the present invention means an oil obtained from fish.
- Fish oil is usually composed mainly of triglycerides containing docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), eicosatetraenoic acid and the like as constituent fatty acids. Free fatty acids, cholesterol and the like may be included.
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- Free fatty acids, cholesterol and the like may be included.
- the fish oil used in the present invention is not limited to its origin and production method.
- the fish oil may be sardine oil, tuna oil, saury oil, herring oil, mackerel oil.
- unrefined fish oil may be used, or purified fish oil may be used, but purified fish oil is preferably used.
- refined fish oil the content of free fatty acids and cholesterol is low.
- Refined fish oils include DHA-22, DHA-22K, DHA-22HG, DHA-KHG, DHA-46A, DHA-50, DHA-70, DHA-27W, DHA-46MK, EPA-18MN, EPA-28MN.
- EPA-28MNSP-E (manufactured by Maruha Nichiro Foods Co., Ltd.), DHA-27, DHA-46A, DHA-55, DHA-70 (manufactured by Nippon Suisan Co., Ltd.) and the like can be used.
- the fish oil used in the present invention may be composed of one type of fat or oil, or may be a mixture of two or more types of fat.
- wheat germ oil oil obtained from wheat germ.
- the production method of wheat germ oil is well established, and wheat germ oil can be easily obtained commercially.
- the amount of fish oil and / or wheat germ oil in the oil and fat composition is not particularly limited, but a typical amount is 30 to 99% by weight, preferably 40 to 80% by weight.
- the ratio of the total weight of sesamin and the total weight of the ⁇ -oryzanol in the composition of the present invention is preferably 1: 0.05 to 1: 100, more preferably 1: 0.05 to 1:10, More preferably, it is 1: 0.1 to 1:10, more preferably 1: 0.2 to 1: 5, and more preferably 1: 0.25 to 1: 1.3.
- the weight of fish oil and / or wheat germ oil when the total weight of sesamin in the composition of the present invention is 1, is preferably 100 or less, more preferably 95 or less, more preferably 90 or less, more preferably 80. It is as follows.
- the weight of fish oil and / or wheat germ oil when the total weight of sesamin is 1 is typically 1 or more, 10 or more, 20 or more, or 30 or more.
- the weight of fish oil and / or wheat germ oil when the total weight of sesamin is 1 may be within a numerical range constituted by an arbitrary combination of these upper and lower limits. For example, it may be in the range of 1-100, 1-95, 10-90, 20-80, or 30-80. Alternatively, the ratio may be 1:35 to 1:47.
- composition of the present invention may contain optional components in addition to fish oil, wheat germ oil, sesamin and ⁇ -oryzanol as long as the effect is not impaired.
- vitamins such as vitamin E and vitamin C, minerals, nutrients, fragrances, preservatives, stabilizers, antioxidants and the like can be appropriately blended.
- the composition of the present invention is expected to exhibit various health functions (or physiological actions) possessed by sesamins, fish oil, wheat germ oil, and ⁇ -oryzanol, for example, health foods, functional foods (specialized foods) Health foods, conditional special health foods, functional nutrition foods), special-purpose foods, health supplements, and the like. Moreover, it can be used for fat processed foods as well as general edible fats and oils.
- the processed oil / fat food refers to a food processed by blending the above oil / fat composition with other food ingredients.
- composition of the present invention is not particularly limited. It can be used in the form of capsule, candy, drop, etc. For example, it can be used as an internal composition of capsules (particularly soft capsules).
- the oil and fat composition of the present invention has various health functions (components involved) due to health component (participating components) such as sesamin, ⁇ -oryzanol, fish oil (more specifically, DHA, EPA). (Or physiological action).
- health component such as sesamin, ⁇ -oryzanol, fish oil (more specifically, DHA, EPA).
- the health functional component refers to a component that is useful for maintaining and promoting health by ingesting a certain amount. Therefore, the composition of this invention can be used for the use resulting from such a health functional ingredient.
- the present invention provides an antioxidant, a hyperlipidemia preventive or ameliorating agent, a liver function improving agent, a hypertension preventive or ameliorating agent, an antihyperdrosis agent, an antiaging agent, an antifatigue agent, a blood LDL Cholesterol lowering agent, blood neutral lipid lowering agent, thrombosis preventing agent, arteriosclerosis preventing agent, learning ability or memory improvement agent, senile dementia preventing agent, gastric mucosa protective agent, endocrine regulator, autonomic nerve regulator, Psychosomatic prevention or improvement agent, cardiac function maintenance agent, blood flow improvement agent, platelet aggregation inhibitor, vascular endothelial function improvement agent, visual function maintenance agent, stress symptom improvement agent, depressive symptom improvement agent, after trauma At least one kind of stress disorder symptom improving agent, endurance improving agent, energy producing agent, frailty preventive agent, skin health maintenance agent, hair health maintenance agent, or life extension agent With sesamin And at least one ⁇ - oryzanol
- Another aspect of the present invention is to prevent body oxidation, prevent or improve hyperlipidemia, improve liver function, prevent or improve hypertension, prevent sickness, prevent aging, prevent or improve fatigue, blood LDL cholesterol Decrease, neutral lipid in blood, prevention of thrombosis, prevention of arteriosclerosis, improvement of learning ability or memory ability, prevention of senile dementia, protection of gastric mucosa, regulation of endocrine, regulation of autonomic nerves, mind and body Prevention or improvement of heart disease, maintenance of cardiac function, improvement of blood flow, suppression of platelet aggregation, improvement of vascular endothelial function, maintenance of visual function, improvement of stress symptoms, improvement of depressive symptoms, improvement of symptoms of post-traumatic stress disorder, endurance At least one sesamin and at least one gamma to improve strength, produce energy, prevent frailty (weakness due to aging), maintain skin health, maintain hair health, or prolong life And oryzanol, fat composition containing a fish oil and / or wheat germ oil, more particularly food products.
- Another aspect of the present invention is to prevent body oxidation, prevent or improve hyperlipidemia, improve liver function, prevent or improve hypertension, prevent sickness, prevent aging, prevent or improve fatigue, blood LDL cholesterol Decrease, neutral lipid in blood, prevention of thrombosis, prevention of arteriosclerosis, improvement of learning ability or memory ability, prevention of senile dementia, protection of gastric mucosa, regulation of endocrine, regulation of autonomic nerves, mind and body Prevention or improvement of heart disease, maintenance of cardiac function, improvement of blood flow, suppression of platelet aggregation, improvement of vascular endothelial function, maintenance of visual function, improvement of stress symptoms, improvement of depressive symptoms, improvement of symptoms of post-traumatic stress disorder, endurance At least one with an indication that it is used to improve strength, produce energy, prevent frailty (weakness due to aging), maintain skin health, maintain hair health, or extend lifespan Of a sesamin-class compound and at least one ⁇ - oryzanol, fat composition containing a fish oil and / or
- the present invention provides an antioxidant, a hyperlipidemia preventive or ameliorating agent, a liver function improving agent, a hypertension preventive or ameliorating agent, an intoxication preventing agent, an antiaging agent, an anti-fatigue agent, a blood LDL cholesterol lowering Agent, blood neutral lipid lowering agent, thrombosis prevention agent, arteriosclerosis prevention agent, learning ability or memory improvement agent, senile dementia prevention agent, gastric mucosal protective agent, endocrine regulator, autonomic nerve regulator, psychosomatic disorder Prevention or improvement agent, cardiac function maintenance agent, blood flow improvement agent, platelet aggregation inhibitor, vascular endothelial function improvement agent, visual function maintenance agent, stress symptom improvement agent, depressive symptom improvement agent, post-traumatic stress disorder At least one sesamin as a symptom-improving agent, endurance-improving agent, energy-producing agent, frailty-preventing agent, skin health maintenance agent, hair health maintenance agent, or life extension agent And at least And one of ⁇ - oryzanol
- the present invention prevents body oxidation in a subject, prevents or improves hyperlipidemia, improves liver function, prevents or improves hypertension, prevents intoxication, prevents aging, prevents or improves fatigue, LDL cholesterol reduction, blood neutral lipid reduction, prevention of thrombosis, prevention of arteriosclerosis, improvement of learning ability or memory, prevention of senile dementia, protection of gastric mucosa, regulation of endocrine, regulation of autonomic nerve , Prevention or improvement of psychosomatic disorders, maintenance of cardiac function, improvement of blood flow, suppression of platelet aggregation, improvement of vascular endothelial function, maintenance of visual function, improvement of stress symptoms, improvement of depressive symptoms, improvement of symptoms of post-traumatic stress disorder , At least one kind of sesamin, for the purpose of improving endurance, producing energy, preventing frailty (weakness due to aging), maintaining skin health, maintaining hair health, or extending lifespan Also a kind of ⁇ - oryzanol, fat composition containing
- the ratio, blending amount, and the like of sesamin, ⁇ -oryzanol, fish oil, and wheat germ oil to be used can be appropriately determined based on the above-described numerical values for the oil and fat composition.
- the types of sesamin, ⁇ -oryzanol, fish oil and wheat germ oil used are the same.
- Sesamin can bring about an antioxidant effect, a hyperlipidemia prevention or improvement effect, a liver function improvement effect, a hypertension prevention or improvement effect, an intoxication prevention effect, an aging prevention effect, and an anti-fatigue effect. See for example WO 2006/106926.
- DHA and EPA prevent or improve hyperlipidemia, lower blood LDL cholesterol, lower blood neutral lipid, prevent thrombosis, prevent arteriosclerosis, improve learning ability or memory, senile dementia Prophylactic effect, cardiac function maintenance effect may be brought about
- cardiac function maintenance effect may be brought about
- Japanese Patent Application Laid-Open No. 2007-89522 see Japanese Patent Application Laid-Open No. 2007-89522.
- ⁇ -Oryzanol can bring about gastric mucosa protective action, endocrine regulation action, autonomic nerve regulation action, psychosomatic disorder prevention or improvement action.
- Antioxidants include in vivo reactive oxygen scavengers, in vivo lipid peroxide production inhibitors and the like. Antioxidants and antioxidants in the body can be expressed as “prevention or suppression of body rust (agent)”, “internal rust removal (component)”, and the like.
- Antioxidants are also useful as anti-aging agents and anti-fatigue agents.
- Anti-aging includes preventing skin aging.
- the anti-fatigue agent of the present invention means a composition for preventing or improving fatigue, and this includes a composition for reducing or recovering fatigue.
- the term “fatigue” in the present invention means a temporary physical and mental performance deterioration phenomenon observed when a physical or mental load is continuously applied. Further, “fatigue” of the present invention includes chronic fatigue syndrome and death from overwork.
- Anti-aging (agent), anti-fatigue agent, and prevention or improvement of fatigue for example, "youthful life (component)", “youthful (component)", “youthfulness It can be expressed as (component) for maintenance or recovery.
- Hyperlipemia prevention or improvement (agent), blood LDL cholesterol lowering (agent), blood neutral lipid lowering (agent), thrombosis prevention (agent) (Component) ”and the like.
- the thrombosis includes cerebral infarction and myocardial infarction.
- “Improving learning ability or memory (agent) and preventing senile dementia (agent) can be expressed as“ maintaining brain power (agent) ”.
- the maintenance of cardiac function can be expressed as “for smooth heart function (component)”.
- the present invention is a method for improving the solubility of sesamins in an oil and fat composition comprising at least one sesamin and fish oil and / or wheat germ oil, the composition And ⁇ -oryzanol.
- the method preferably further comprises a step of adjusting the ratio of the total weight of sesamin and the total weight of ⁇ -oryzanol in the oil and fat composition.
- the ratio is preferably 1: 0.05 to 1: 100, more preferably 1: 0.05 to 1:10, more preferably 1: 0.1 to 1:10, and still more preferably 1: 0.2. To 1: 5, even more preferably 1: 0.25 to 1: 1.3.
- ⁇ -oryzanol is contained in the finally obtained oil and fat composition.
- the ratio between the amount of sesamin and the amount of ⁇ -oryzanol may be within a desired range in the finally obtained fat composition. Therefore, means for blending ⁇ -oryzanol and means for adjusting the ratio of each component are not limited, and any method known to those skilled in the art may be used. Further, the timing is not limited. For example, it is conceivable to add ⁇ -oryzanol before, during or after any of the steps for producing the oil and fat composition.
- Example 1 ⁇ Crystal precipitation method>
- DHA-containing purified fish oil DHA-55, manufactured by Nihon Suisan
- wheat germ oil summit
- Oil Refinery Co., Ltd. DHA-containing purified fish oil
- ⁇ -oryzanol Wako Pure Chemical Industries, Ltd.
- rice germ oil gamma 30S Tsukino Food Industry Co., Ltd.
- Rice germ oil gamma 30S was used in an amount capable of supplying 50 mg and 200 mg of ⁇ -oryzanol.
- the amount of each of the test sample and the comparative sample was adjusted to a total of 10 g with a solvent oil and fat, and heated to 85 ° C. to completely dissolve sesamin. Thereafter, it was stored at 5 ° C. for 1 week.
- the liquid containing the precipitated crystals was subjected to suction filtration for solid-liquid separation, and then ethanol was added to the obtained crystals to wash out the oils and fats.
- the weight of the crystals obtained by these operations was measured. Tables 1A, 1B and 2 show the crystal weights obtained from each test sample.
- This measuring method can confirm the oryzanol content in the precipitated crystals.
- ⁇ -oryzanol cycloartyl ferulate standard product, Wako Pure Chemical Industries, Ltd.
- heptane was added to make 100 mL.
- 8 mg of crystals obtained from each sample were also weighed, and heptane was added to make 100 mL.
- Each was dissolved by ultrasonic treatment and then diluted 10 times to obtain a measurement liquid. Next, the absorbance (315 nm) of the liquid was measured.
- ⁇ -oryzanol can enhance the solubility of sesamin in fish oil and / or wheat germ oil.
- solubility of sesamin was enhanced by using a rice germ oil solution of ⁇ -oryzanol rather than using ⁇ -oryzanol alone.
- the numerical range represented by the upper limit value and the lower limit value in this specification includes the lower limit value and the upper limit value.
- the range represented by “1-2” includes 1 and 2. This is also true for each ratio value.
Abstract
Description
1.少なくとも一種のセサミン類と、少なくとも一種のγ-オリザノールと、魚油及び/又は小麦胚芽油とを含有する油脂組成物。
2.当該セサミン類の総重量:当該γ-オリザノールの総重量=1:0.05~1:100である、1に記載の組成物。
3.当該セサミン類の総重量を1とした場合の当該魚油及び/又は小麦胚芽油の重量が100以下である、1又は2に記載の組成物。
4.当該セサミン類がセサミンおよび/またはエピセサミンである、1~3のいずれか1項に記載の組成物。
5.当該γ-オリザノールが米胚芽油の形態で含まれている、1~4のいずれか1項に記載の組成物。
6.飲食品である、1~5のいずれか1項に記載の組成物。
7.セサミン類、γ-オリザノール、及び魚油からなる群から選択される少なくとも一種を保健機能成分(関与成分)とする機能表示を付した、6に記載の飲食品。
8.抗酸化剤、高脂血症予防もしくは改善剤、肝機能改善剤、高血圧予防もしくは改善剤、悪酔防止剤、老化防止剤、抗疲労剤、血中LDLコレステロール低下剤、血中中性脂質低下剤、血栓症予防剤、動脈硬化予防剤、学習能力もしくは記憶力向上剤、老人性痴呆症予防剤、胃粘膜保護剤、内分泌調節剤、自律神経調節剤、心身症予防もしくは改善剤、心臓機能維持剤、血流改善剤、血小板凝集抑制剤、血管内皮機能改善剤、視機能の維持剤、ストレス症状の改善剤、うつ症状の改善剤、心的外傷後ストレス障害症状の改善剤、持久力向上剤、エネルギー産生剤、フレイルティ(高齢による衰弱)の予防剤、肌の健康維持剤、髪の健康維持剤、又は寿命の延長剤である、1~7のいずれか1項に記載の組成物。
9.体内酸化の防止、高脂血症の予防もしくは改善、肝機能の改善、高血圧の予防もしくは改善、悪酔防止、老化防止、疲労の予防もしくは改善、血中LDLコレステロールの低下、血中中性脂質の低下、血栓症の予防、動脈硬化の予防、学習能力もしくは記憶力の向上、老人性痴呆症の予防、胃粘膜の保護、内分泌の調節、自律神経の調節、心身症の予防もしくは改善、心臓機能の維持、血流改善、血小板凝集抑制、血管内皮機能改善、視機能の維持、ストレス症状の改善、うつ症状の改善、心的外傷後ストレス障害症状の改善、持久力向上、エネルギー産生、フレイルティ(高齢による衰弱)の予防、肌の健康維持、髪の健康維持、又は寿命の延長のために用いられるものである旨の表示を付した、6又は7に記載の飲食品。
10.抗酸化剤、高脂血症予防もしくは改善剤、肝機能改善剤、高血圧予防もしくは改善剤、悪酔防止剤、老化防止剤、抗疲労剤、血中LDLコレステロール低下剤、血中中性脂質低下剤、血栓症予防剤、動脈硬化予防剤、学習能力もしくは記憶力向上剤、老人性痴呆症予防剤、胃粘膜保護剤、内分泌調節剤、自律神経調節剤、心身症予防もしくは改善剤、心臓機能維持剤、血流改善剤、血小板凝集抑制剤、血管内皮機能改善剤、視機能の維持剤、ストレス症状の改善剤、うつ症状の改善剤、心的外傷後ストレス障害症状の改善剤、持久力向上剤、エネルギー産生剤、フレイルティ(高齢による衰弱)の予防剤、肌の健康維持剤、髪の健康維持剤、又は寿命の延長剤としての、1~7のいずれか1項に記載の組成物の使用。
11.対象における体内酸化の防止、高脂血症の予防もしくは改善、肝機能の改善、高血圧の予防もしくは改善、悪酔防止、老化防止、疲労の予防もしくは改善、血中LDLコレステロールの低下、血中中性脂質の低下、血栓症の予防、動脈硬化の予防、学習能力もしくは記憶力の向上、老人性痴呆症の予防、胃粘膜の保護、内分泌の調節、自律神経の調節、心身症の予防もしくは改善、心臓機能の維持、血流改善、血小板凝集抑制、血管内皮機能改善、視機能の維持、ストレス症状の改善、うつ症状の改善、心的外傷後ストレス障害症状の改善、持久力向上、エネルギー産生、フレイルティ(高齢による衰弱)の予防、肌の健康維持、髪の健康維持、又は寿命の延長のための、1~7のいずれか1項に記載の組成物を対象に投与することを含む方法。
12.少なくとも一種のセサミン類と魚油及び/又は小麦胚芽油とを含む油脂組成物における、当該セサミン類の溶解性を向上させるための方法であって、当該組成物にγ-オリザノールを配合することを含む方法。
13.12に記載の方法であって、当該組成物にγ-オリザノールを米胚芽油の形態で配合することを含む方法。
本発明に関連して用いられる「セサミン類」との用語は、セサミン及びその類縁体を含む一連の化合物の総称である。当該セサミン類縁体としては、エピセサミンの他、例えば特開平4-9331号公報に記載されたジオキサビシクロ〔3.3.0〕オクタン誘導体がある。セサミン類の具体例としては、セサミン、エピセサミン、セサミノール、エピセサミノール、セサモリン等を例示でき、これらの立体異性体又はラセミ体を単独で、または混合して使用することができるが、本発明においては、セサミン及び/又はエピセサミンを好適に用いることができる。
セサミン類の溶解性を向上させるのに重要な成分はγ-オリザノールである。γ-オリザノールには血中中性脂質低下作用(Geriant.med. 19, 1812-1840, 1981)や、内分泌・自律神経調節作用(日薬理誌、75(4)、399-403, 1979)、胃粘膜保護作用(日薬理誌、84(6)、537-542, 1984)などの様々な生理作用が知られており、精製されたものは高脂血症治療剤や心身症(更年期障害、過敏性大腸症候群)治療剤などの医薬品として認可されている。本発明に関連して用いられる「γ-オリザノール」との用語は、フェルラ酸にトリテルペンアルコールまたは植物ステロールがエステル結合したものの総称である。前記のトリテルペンアルコールとしては、例えば、シクロアルテノール、24-メチレンシクロアルタノール、シクロアルタノール、シクロプラノール等を挙げることができ、植物ステロールとしては、カンペステロール、スチグマステロール、β-シトステロール等を例示することができる。本発明においては、これらの化合物を単独で用いることもできるし、混合物として使用することもできる。
本発明に関連して用いられる「魚油」との用語は、魚から得られる油脂を意味する。魚油は、通常、ドコサヘキサエン酸(DHA)、エイコサペンタエン酸(EPA)、ドコサペンタエン酸(DPA)、エイコサテトラエン酸等を構成脂肪酸とするトリグリセリドを主成分とし、さらに、魚油には種々の遊離脂肪酸、コレステロール等が含まれ得る。
本発明に関して用いられる「小麦胚芽油」との用語は、小麦の胚芽から得られる油を意味する。小麦胚芽油の製造方法はよく確立されており、また、小麦胚芽油は商業的に容易に入手することもできる。
本発明において、セサミン類の溶解性の向上は、セサミン類とγ-オリザノールとが特定比率で存在するときに顕著となる。本発明の組成物中のセサミン類の総重量と当該γ-オリザノールの総重量との比率は、好ましくは1:0.05~1:100、より好ましくは1:0.05~1:10、より好ましくは1:0.1~1:10、より好ましくは1:0.2~1:5、より好ましくは1:0.25~1:1.3である。
本発明の組成物は、その効果を損なわない限り、魚油、小麦胚芽油、セサミン類およびγ-オリザノールの他に、任意の成分を配合してもよい。例えば、ビタミンE、ビタミンC等のビタミン類、ミネラル類、栄養成分、香料、防腐剤、安定化剤、抗酸化剤等を適宜配合することができる。
本発明の組成物は、セサミン類、魚油、小麦胚芽油、γ-オリザノールが有する各種の保健機能(又は生理作用)を発揮することが期待されるため、例えば、健康食品、機能性食品(特定保健用食品、条件付き特定保健用食品、栄養機能食品が含まれる)、特別用途食品、健康補助食品等として好適に利用できる。また、一般の食用油脂と同様、油脂加工食品に用いることができる。ここで油脂加工食品とは、上記油脂組成物に他の食品原料を配合し、加工した食品をいう。
本発明は、別の側面では、少なくとも一種のセサミン類と魚油及び/又は小麦胚芽油、とを含む油脂組成物における、当該セサミン類の溶解性を向上させるための方法であって、当該組成物にγ-オリザノールを配合することを含む方法である。当該方法は、好ましくは、油脂組成物中のセサミン類の総重量とγ-オリザノールの総重量との比率を調整する工程をさらに含む。当該比率は、好ましくは1:0.05~1:100、より好ましくは1:0.05~1:10、より好ましくは1:0.1~1:10、さらに好ましくは1:0.2~1:5、さらにより好ましくは1:0.25~1:1.3である。
<結晶の析出方法>
試験サンプル及び比較サンプルの調製のため、下記の表1A、1B又は2に示されている通りの量のセサミンをDHA含有精製魚油(DHA-55、日本水産株式会社製)又は小麦胚芽油(サミット製油株式会社)に加えた。さらに、試験サンプルについては、表1A、1B又は2に記載の量でγ-オリザノール(和光純薬工業株式会社)または米胚芽油ガンマ30S(築野食品工業株式会社)を加えた。米胚芽油ガンマ30Sは、γ-オリザノールを50mg及び200mg供給することのできる量で用いた。
この測定方法は、析出した結晶中のオリザノール含量を確認することができる。
上記の結果から、γ-オリザノールが、魚油及び/又は小麦胚芽油中のセサミン類の溶解性を高めることができることが明らかとなった。また、γ-オリザノール単体を用いるよりも、γ-オリザノールの米胚芽油溶液を用いる方が、セサミン類の溶解性は高まった。
ゼラチン 60.0%
グリセリン 30.0%
パラオキシ安息香酸メチル 0.15%
パラオキシ安息香酸プロピル 0.51%
水 適量
セサミン(セサミン:エピセサミン=1:1) 10mg
グリセリン脂肪酸エステル 15.0mg
ミツロウ 15.0mg
γ-オリザノール 1.0、2.0、2.5、13.0、50.0又は100.0mg、
魚油 1000mg
製剤例1と同じソフトカプセル剤皮の中に、以下に示す、セサミン類が溶解した油脂組成物を常法により充填し、ソフトカプセルを得た。
セサミン(セサミン:エピセサミン=1:1) 10mg
グリセリン脂肪酸エステル 15.0mg
ミツロウ 15.0mg
γ-オリザノール 1.0、2.0、2.5、13.0、50.0又は100.0mg、
小麦胚芽油 500mg
製剤例1と同じソフトカプセル剤皮の中に、以下に示す、セサミン類が溶解した油脂組成物を常法により充填し、ソフトカプセルを得た。
セサミン(セサミン:エピセサミン=1:1) 10mg
グリセリン脂肪酸エステル 15.0mg
ミツロウ 15.0mg
米胚芽油ガンマ30S
γ-オリザノールを1.0、2.0、2.5、13.0、50.0又は100.0mgを提供する量
魚油 500mg
製剤例1と同じソフトカプセル剤皮の中に、以下に示す、セサミン類が溶解した油脂組成物を常法により充填し、ソフトカプセルを得た。
セサミン(セサミン:エピセサミン=1:1) 10mg
グリセリン脂肪酸エステル 15.0mg
ミツロウ 15.0mg
米胚芽油ガンマ30S
γ-オリザノールを1.0、2.0、2.5、13.0、50.0又は100.0mgを提供する量
小麦胚芽油 1000mg
Claims (9)
- 少なくとも一種のセサミン類と、少なくとも一種のγ-オリザノールと、魚油及び/又は小麦胚芽油とを含有する油脂組成物。
- 当該セサミン類の総重量:当該γ-オリザノールの総重量=1:0.05~1:100である、請求項1に記載の組成物。
- 当該セサミン類の総重量を1とした場合の当該魚油及び/又は小麦胚芽油の重量が100以下である、請求項1又は2に記載の組成物。
- 当該セサミン類がセサミンおよび/またはエピセサミンである、請求項1~3のいずれか1項に記載の組成物。
- 当該γ-オリザノールが米胚芽油の形態で含まれている、請求項1~4のいずれか1項に記載の組成物。
- 飲食品である、請求項1~5のいずれか1項に記載の組成物。
- セサミン類、γ-オリザノール、及び魚油からなる群から選択される少なくとも一種を保健機能成分(関与成分)とする機能表示を付した、請求項6に記載の飲食品。
- 少なくとも一種のセサミン類と魚油及び/又は小麦胚芽油とを含む油脂組成物における、当該セサミン類の溶解性を向上させるための方法であって、当該組成物にγ-オリザノールを配合することを含む方法。
- 請求項8に記載の方法であって、当該組成物にγ-オリザノールを米胚芽油の形態で配合することを含む方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480068539.9A CN105828623B (zh) | 2013-12-16 | 2014-12-16 | 富含芝麻素类的组合物 |
US15/104,549 US10159740B2 (en) | 2013-12-16 | 2014-12-16 | Compositions with high content of sesamin class compounds |
JP2015553555A JP6537975B2 (ja) | 2013-12-16 | 2014-12-16 | セサミン類高含有組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-259205 | 2013-12-16 | ||
JP2013259205 | 2013-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015093484A1 true WO2015093484A1 (ja) | 2015-06-25 |
Family
ID=53402829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/083272 WO2015093484A1 (ja) | 2013-12-16 | 2014-12-16 | セサミン類高含有組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10159740B2 (ja) |
JP (1) | JP6537975B2 (ja) |
CN (1) | CN105828623B (ja) |
TW (1) | TWI669062B (ja) |
WO (1) | WO2015093484A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020202835A (ja) * | 2020-07-15 | 2020-12-24 | 株式会社神明きっちん | 肌保湿用食品組成物及び肌保湿用食品組成物の摂取方法 |
WO2023223943A1 (ja) * | 2022-05-16 | 2023-11-23 | サントリーホールディングス株式会社 | 血管内皮機能改善用組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114013A1 (ja) * | 2006-03-31 | 2007-10-11 | Suntory Limited | リグナン類化合物含有組成物 |
JP2009073749A (ja) * | 2007-09-19 | 2009-04-09 | Suntory Ltd | セサミン類とγ−オリザノールとを含有する組成物 |
JP2010150209A (ja) * | 2008-12-26 | 2010-07-08 | Suntory Holdings Ltd | セサミン類とエピガロカテキンガレートとを含有する組成物 |
WO2013122122A1 (ja) * | 2012-02-15 | 2013-08-22 | 株式会社明治 | 乳飲料及びその製造方法 |
WO2013187391A1 (ja) * | 2012-06-14 | 2013-12-19 | サントリーホールディングス株式会社 | セサミン類とγ-オリザノールと米胚芽油とを含有する組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172106B1 (en) * | 1998-02-09 | 2001-01-09 | R. Armour Forse | Sesamol inhibition of Δ-5-desaturase activity and uses therefor |
ES2385597T3 (es) * | 2000-12-21 | 2012-07-27 | Aarhuskarlshamn Denmark A/S | Procedimiento para la preparación de fracciones de aceite vegetal ricas en materia insaponificable, no tocólica, de alto punto de fusión |
US7776915B2 (en) * | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
CA2603347C (en) * | 2005-03-31 | 2014-06-17 | Suntory Limited | Oil-in-water emulsions of lignans that exhibit improved absorption rate |
JPWO2007013690A1 (ja) * | 2005-07-28 | 2009-02-12 | 味の素株式会社 | 顧客に適する局所塗布剤とサプリメントとを提供する方法 |
CN101331901B (zh) * | 2008-07-28 | 2011-02-09 | 上海良友(集团)有限公司 | 一种脂肪酸比例合理的组合食用油 |
US20130237508A1 (en) * | 2010-11-09 | 2013-09-12 | Takuo Tsuno | METHOD FOR PRODUCING y-ORYZANOL-CONTAINING FAT OR OIL |
JP5735576B2 (ja) * | 2013-05-17 | 2015-06-17 | サントリーホールディングス株式会社 | コエンザイムq10を含有する組成物 |
-
2014
- 2014-12-16 TW TW103143886A patent/TWI669062B/zh active
- 2014-12-16 CN CN201480068539.9A patent/CN105828623B/zh active Active
- 2014-12-16 US US15/104,549 patent/US10159740B2/en active Active
- 2014-12-16 WO PCT/JP2014/083272 patent/WO2015093484A1/ja active Application Filing
- 2014-12-16 JP JP2015553555A patent/JP6537975B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114013A1 (ja) * | 2006-03-31 | 2007-10-11 | Suntory Limited | リグナン類化合物含有組成物 |
JP2009073749A (ja) * | 2007-09-19 | 2009-04-09 | Suntory Ltd | セサミン類とγ−オリザノールとを含有する組成物 |
JP2010150209A (ja) * | 2008-12-26 | 2010-07-08 | Suntory Holdings Ltd | セサミン類とエピガロカテキンガレートとを含有する組成物 |
WO2013122122A1 (ja) * | 2012-02-15 | 2013-08-22 | 株式会社明治 | 乳飲料及びその製造方法 |
WO2013187391A1 (ja) * | 2012-06-14 | 2013-12-19 | サントリーホールディングス株式会社 | セサミン類とγ-オリザノールと米胚芽油とを含有する組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020202835A (ja) * | 2020-07-15 | 2020-12-24 | 株式会社神明きっちん | 肌保湿用食品組成物及び肌保湿用食品組成物の摂取方法 |
WO2023223943A1 (ja) * | 2022-05-16 | 2023-11-23 | サントリーホールディングス株式会社 | 血管内皮機能改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2015093484A1 (ja) | 2017-03-16 |
JP6537975B2 (ja) | 2019-07-03 |
CN105828623B (zh) | 2020-08-07 |
US10159740B2 (en) | 2018-12-25 |
TWI669062B (zh) | 2019-08-21 |
US20160310599A1 (en) | 2016-10-27 |
CN105828623A (zh) | 2016-08-03 |
TW201528959A (zh) | 2015-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6879597B2 (ja) | 脂質含有組成物およびその使用方法 | |
AU2007212412B2 (en) | Dietary supplement composition for blood lipid health | |
JP5118965B2 (ja) | 植物成分を必要とする治療方法 | |
JP2002540221A (ja) | 海洋源からの精製されたトリグリセリドを、穏やかな安定性油に変換するプロセス | |
WO2007037438A1 (ja) | メタボリックシンドローム改善・予防組成物 | |
JP2006016408A (ja) | 血中中性脂肪抑制剤 | |
JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
US20230310470A1 (en) | Intelligent delivery of ingested and absorbed molecules | |
US20160243185A1 (en) | Bioactive-rich concentrates and nutritive and therapeutic products containing same | |
JP6537975B2 (ja) | セサミン類高含有組成物 | |
JP6157463B2 (ja) | セサミン類とγ−オリザノールと米胚芽油とを含有する組成物 | |
JP6450317B2 (ja) | Dha及びepaを含む軟カプセル | |
CN106535650A (zh) | 磷虾油制剂和它们的用途 | |
JP4394174B2 (ja) | 炎症性腸疾患治療剤 | |
JP2006306820A (ja) | 低密度リポタンパク質(ldl)酸化抑制剤 | |
US20080161413A1 (en) | Agent for increasing adiponectin in blood | |
FR2865353A1 (fr) | Nouveaux complements dietetiques ou alimentaires a base d'acide gras insature et leurs utilisation | |
US20120135104A1 (en) | Enhanced Absorption of Omega Fatty Acid Oils | |
US20110319467A1 (en) | Absorption Enhancement of Statins and Omega Fatty Acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14872865 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015553555 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15104549 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14872865 Country of ref document: EP Kind code of ref document: A1 |